Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator.

@article{Ellis1985ImmunocytochemicalSO,
  title={Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator.},
  author={Ian O. Ellis and C. P. Hinton and J. Macnay and Christopher W. Elston and Adrian R. Robins and A. A. Owainati and Roger W. Blamey and Robert W. Baldwin and Berne Ferry},
  journal={British medical journal},
  year={1985},
  volume={290 6472},
  pages={
          881-3
        }
}
The staining of breast cancer with a new monoclonal antibody, NCRC 11, was studied in a series of 126 women with primary breast carcinoma. Tumour samples embedded in paraffin were tested, and the minimum duration of follow up was five years or to death. Altogether 119 tumours stained positively. There was a strong relation between the intensity of staining, divided on a four point scale, and patient survival. Patients whose tumours exhibited intense staining had an improved survival compared… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas.

  • Pathology, research and practice
  • 2001
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.

  • British Journal of Cancer
  • 1987
VIEW 3 EXCERPTS
CITES METHODS, RESULTS & BACKGROUND
HIGHLY INFLUENCED